IPHA 6-K: SEC filing
Innate Pharma S.A.
Filed with the SEC on · accession 0001628280-26-073032
IPHA filed a 6-K (foreign company report) with the SEC on Nov 12, 2026. Innate Pharma S.A. filed a Form 6-K with the SEC on November 11, 2026, attaching a press release dated the same day.
Summary of the filing
Innate Pharma S.A. filed a Form 6-K with the SEC on November 11, 2026, attaching a press release dated the same day. The filing itself contains no substantive operational or financial details beyond the exhibit reference and signature by CEO Jonathan Dickinson.
Key details
✦ Ask GOAX AI about this filing — what it means for IPHA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for IPHA?
Click hereFrequently asked questions
What did IPHA file with the SEC on Nov 12, 2026?
IPHA filed a 6-K (SEC filing). Innate Pharma S.A. filed a Form 6-K with the SEC on November 11, 2026, attaching a press release dated the same day. The filing itself contains no substantive operational or financial details beyond the exhibit reference and signature by CEO Jonathan Dickinson.
How do I read a 6-K?
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Other IPHA SEC filings
Get alerts when IPHA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days